Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.63 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116673 | 1.00 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL22666389 | 1.00 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL29521573 | 1.00 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2610712 | 0.90 | HCRTR1 (0.52) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2610413 | 0.89 | HCRTR1 (0.60) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL19866895 | 0.89 | HCRTR1 (0.60) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL15213606 | 0.87 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL22666385 | 0.87 | HCRTR1 (0.63) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL20859668 | 0.87 | HCRTR1 (0.65) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL18198316 | 0.87 | HCRTR1 (0.65) | HCRTR1HCRTR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178693-A1 | METHOD FOR PREPARING LEMBOREXANT AND METHOD FOR PREPARING LEMBOREXANT INTERMEDIATE | 浙江华海药业股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| WO-2020230800-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2020-11-19 | — | — | WO | disclosed |
| US-10065930-B2 | Method for producing pyrimidine-1-ol compound, and intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-09-04 | — | — | US | disclosed |
| US-20170204068-A1 | METHOD FOR PRODUCING PYRIMIDINE-1-OL COMPOUND, AND INTERMEDIATE THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204068-A1 | METHOD FOR PRODUCING PYRIMIDINE-1-OL COMPOUND, AND INTERMEDIATE THEREOF | DPYD, UMPS, TYMS | HCRTR1 4807/4885HCRTR2 4720/4885KCNH2 3811/4885 |
| US-10065930-B2 | Method for producing pyrimidine-1-ol compound, and intermediate thereof | DPYD, UMPS, TYMS | HCRTR1 4807/4885HCRTR2 4720/4885KCNH2 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.